Drugs / AltSonflex1-2-3
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05073003 | Oct 2021 → Jun 2025 | diarrheal disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07320716 | Jan 2026 → Oct 2028 expected | diarrheal disease | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06663436 | Nov 2024 → Oct 2025 | diarrheal disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | altSonflex1-2-3 | “BACKGROUND: We report data from stage 1 of an ongoing 2-staged, phase 1/2 randomized clinical trial with a 4-component generalized modules for membrane antigens-based vaccine...” PMID 38853614 ↗ Oct 2024 |
| Modality | Vaccine | “The aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S....” NCT05073003 ↗ |
| Route | Intramuscular | “altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169” NCT06663436 ↗ |